Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
Dhruv MahttaDavid J RamseyMichelle T LeeLiang ChenMahmoud Al RifaiJulia M AkeroydElizabeth M VaughanMichael E MathenyKarla Rodrigues do Espirito SantoSankar D NavaneethanCarl J LavieYochai BirnbaumChristie M BallantyneLaura A PetersenSalim S ViraniPublished in: Diabetes care (2022)
Overall utilization rates of SGLT2i and GLP-1 RA among eligible patients are low, with significantly higher residual facility-level variation in the use of these drug classes. Our results suggest opportunities to optimize their use to prevent future adverse cardiovascular events among these patients.
Keyphrases
- cardiovascular disease
- cardiovascular events
- end stage renal disease
- type diabetes
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- rheumatoid arthritis
- emergency department
- skeletal muscle
- systemic lupus erythematosus
- systemic sclerosis
- weight loss
- idiopathic pulmonary fibrosis
- ankylosing spondylitis